Recent Posts

• AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer December 9, 2024
• AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema August 23, 2024
• AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer December 11, 2023
• AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors September 18, 2023
• AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors August 30, 2023